Introduction
Vibrio vulnificus is a halophilic marine microorganism which causes gastroenteritis and primary septicaemia in humans. The septicaemia is often acquired by eating raw oysters or shellfish, and wound infections are associated with the exposure of wounds to seawater (Blake et al., 1979; Tacket et al., 1984; Klontz et al., 1988) . Primary septicaemia is often associated with patients who have diseases predisposing them to iron overload, such as liver cirrhosis, haemochromatosis and alcoholism, or who are immunocompromised (Johnston et al., 1985) . V. vulnificus sequesters iron through the biosynthesis and secretion of a low-molecular-weight chelating compound called a siderophore (Morris et al., 1987; Litwin et al., 1996) . V. vulnificus M2799 produces a catecholate siderophore called vulnibactin (Okujo et al., 1994) . The vulnibactin-mediated iron-uptake system plays an important role in the growth of V. vulnificus M2799 under low iron-concentration conditions (Kawano et al., 2013) . Furthermore, the vulnibactin export system is composed of VV1_0612 TolC and several resistance nodulation-division proteins, including the VV1_1681 protein (Kawano et al., 2014) . Vulnibactin chelates ferric iron in the environment, and vulnibactin-Fe 3+ is imported to the periplasm through the specific outer membrane receptor VuuA (Webster & Litwin, 2000) . Subsequently, vulnibacitin-Fe 3+ is captured by a periplasmic binding protein (PBP), FatB, and is transported through the inner membrane by an ABC transporter. In a previous study, we clarified that the VatD protein, which functions as a periplasmic ferric aerobactin-binding protein, participates in the ferric vulnibactin-uptake system in the absence of FatB (Kawano et al., 2013) . VatD can capture both ferric aerobactin and ferric vulnibactin. Therefore, the ISSN 2053-230X # 2015 International Union of Crystallography structural analysis of VatD will be important for elucidation of the iron-uptake system in V. vulnificus M2799. Here, we report the expression, purification, crystallization and preliminary X-ray crystallographic analysis of V. vulnificus VatD. Furthermore, the complex of VatD with desferrioxamine B-Fe 3+ (FOB) was also analysed.
Materials and methods

Macromolecule production
The expression plasmid pProVatD coding for the mature VatD protein was constructed as follows. Two oligonucleotide primers (vatD_Nc and vatD_Xh) were synthesized which were modified to contain NcoI and XhoI recognition sites to facilitate in-frame cloning into the His-tagged protein expression vector pProEX HTa (Invitrogen). PCR was performed by KOD -Plus-DNA polymerase (Toyobo) with the genome of V. vulnificus M2799 as a template for 30 cycles consisting of 367 K for 15 s, 333 K for 30 s and 341 K for 1 min. The amplified DNA was digested by NcoI and XhoI, and the resulting fragment (857 bp) was inserted into the corresponding sites of pProEX HTa. The nucleotide sequence of the PCR fragment was confirmed by DNA sequencing. Escherichia coli BL21(DE3)pLysS cells harbouring pProVatD were induced with 1.0 mM isopropyl -d-1-thiogalactopyranoside at an OD 600 of 0.7 and further incubated overnight at 293 K. The cells were disrupted by sonication and the lysate was centrifuged at 30 000 rev min À1 for 30 min at 277 K. The supernatant was loaded onto an Ni Sepharose 6 Fast Flow column (GE Healthcare) equilibrated with 20 mM Tris-HCl pH 7.5 containing 300 mM NaCl and 50 mM imidazole. The column was washed with five bed volumes of the same buffer. The His-tagged VatD (HisVatD) protein was eluted with 20 mM Tris-HCl pH 7.5 containing 300 mM NaCl and 300 mM imidazole, and treated with AcTEV protease (Invitrogen) overnight at 277 K to obtain VatD. To remove the His tag, the sample was reloaded onto an Ni Sepharose column and the non-adsorbed fraction was pooled. The fraction was dialyzed against 20 mM Tris-HCl pH 8.0 and applied onto a RESOURCE Q column (GE Healthcare). The column was eluted with a linear gradient of 0-1.0 M NaCl in 20 mM Tris-HCl pH 8.0. The VatD protein was collected and further purified by HiLoad 16/600 Superdex 75 pg (GE Healthcare) column chromatography. The N-terminal amino-acid sequence of VatD was confirmed by protein sequencing. The purified apo VatD protein was concentrated to 9 mg ml À1 in 20 mM Tris-HCl pH 7.5 containing 150 mM NaCl using an Amicon Ultra-15 centrifugal filter device (molecular-weight cutoff 10 kDa). Macromolecule-production information is summarized in Table 1 .
Crystallization
Initial crystallization trials were carried out with the commercially available sparse-matrix screening kits Index 
Data collection and processing
Crystals of apo VatD and VatD-FOB were soaked in the crystallization solution supplemented with 20%(v/v) glycerol and were mounted in a cryoloop and flash-cooled in a stream of gaseous nitrogen at 100 K. X-ray diffraction data were collected from apo VatD crystals on beamline BL38B1 at SPring-8, Japan, which was equipped with an ADSC Quantum 315r CCD detector. Data collection was performed at a wavelength of 1.0 Å with a total oscillation range of 180 . Each diffraction image was obtained with an oscillation angle of 1.0 and an exposure time of 30 s. The diffraction data for apo VatD were processed and scaled with the HKL-2000 program package (Otwinowski & Minor, 1997) . Data for VatD-FOB were collected on a Rigaku FR-E + rotating copper-anode X-ray generator equipped with an Osmic confocal mirror and an R-AXIS VII image-plate scanner. The diffraction data for VatD-FOB were processed and scaled with CrystalClear (Rigaku). Details of the data collection and processing and statistics describing the quality of the data are given in Table 3 .
Results and discussion
Recombinant VatD was purified to homogeneity using Niaffinity, anion-exchange and gel-filtration chromatography. The purity of the protein was checked by SDS-PAGE with Coomassie staining (Fig. 1) . The molecular mass of VatD calculated from the deduced amino-acid sequence is in reasonable agreement with that estimated by SDS-PAGE (31 kDa). The protein solution was concentrated to a sufficient level for crystallization. Crystals of apo VatD and VatD-FOB were obtained under several conditions from commercial screening kits. After a series of optimization experiments, the quality of the crystals was improved to a suitable level for X-ray analysis (Fig. 2) .
X-ray diffraction data for apo VatD and VatD-FOB were collected to resolutions of 2.60 and 1.85 Å , respectively, from flash-cooled crystals (Fig. 3) . The crystals of apo VatD belonged to space group P6 4 22, with unit-cell parameters a = b = 151.8, c = 76.1 Å . According to the unit-cell parameters and the molecular weight of VatD, solvent-content analysis suggested one molecule per asymmetric unit, with a V M value of 4.03 Å 3 Da À1 and a solvent content of 69.5% (Matthews, 1968) . The crystals of VatD-FOB belonged to space group P2 1 , with unit-cell parameters a = 34.8, b = 57.9, c = 62.7 Å , = 90.0, = 95.0, = 90.0 . The V M value of 2.03 Å 3 Da À1 indicated that the VatD-FOB crystal contained one protein molecule per asymmetric unit. The data-collection statistics are shown in Table 3 . Interestingly, the crystallization condition and crystal form of VatD-FOB were different from those of apo VatD. These differences could be caused by a conformational change of VatD owing to the binding of FOB.
The molecular-replacement procedure was applied to the structure determination of apo VatD and VatD-FOB and was performed using FhuD from E. coli (PDB entry 1efd; Clarke et al., 2000) as a search model with MOLREP (Vagin & Teplyakov, 2010) from the CCP4 suite (Winn et al., 2011) . The initial maps of both models showed clear electron density. The structures of both apo VatD and VatD-FOB are under construction. 
